US 12016860
Combination therapies with Cbl-b inhibitor compounds
granted A61KA61K2039/505A61K31/337
Quick answer
US patent 12016860 (Combination therapies with Cbl-b inhibitor compounds) held by NURIX THERAPEUTICS, INC. expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- NURIX THERAPEUTICS, INC.
- Grant date
- Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K2039/505, A61K31/337, A61K31/4196, A61K31/454